Charles Magness
Direktor/Vorstandsmitglied bei Kineta One LLC
Vermögen: 397 064 $ am 30.04.2024
Profil
Charles L.
Magness was the founder of Illumigen Biosciences, Inc. (founded in 2000), Kineta, Inc. (Washington) (founded in 2007), and Kineta, Inc. (founded in 2008), where he held the title of President & Chief Operating Officer, President & Chief Executive Officer, and President & Chief Executive Officer, respectively.
Currently, he is a Director at Kineta One LLC.
Magness's former positions include President, Chief Executive Officer & Director at KPI Therapeutics, Inc., Principal at the University of Washington, and Principal at McDonnell Douglas Automation.
He received a doctorate degree from Lehigh University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
KINETA, INC.
5,66% | 31.12.2023 | 620 413 ( 5,66% ) | 397 064 $ | 30.04.2024 |
Aktive Positionen von Charles Magness
| Unternehmen | Position | Beginn |
|---|---|---|
Kineta One LLC
 Kineta One LLC Pharmaceuticals: MajorHealth Technology Kineta One LLC provides biotechnology services. The company is headquartered in Seattle, WA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Charles Magness
| Unternehmen | Position | Ende |
|---|---|---|
Illumigen Biosciences, Inc.
 Illumigen Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Illumigen Biosciences, Inc. provides pharmaceutical research services. It develops human genetic mutations that provide roadmap for therapeutic drug mechanisms. The company's product IB657 helps to investigate the cause of apparent immunity to HCV infection. Illumigen Biosciences was founded by Dr. Charles Magness and Shawn Iadonato in 2000 and is located in Seattle, WA | Gründer | 01.01.2007 |
| KINETA, INC. | Vorstandsvorsitzender | - |
KPI Therapeutics, Inc.
 KPI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KPI Therapeutics, Inc. operates as a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. It offers dalazatide, KPI-150, and KPI-190 for systemic autoimmune diseases including lupus; and CSP conopeptide for chronic pain. The company was founded in 2013 and is headquartered in Seattle, WA. | Vorstandsvorsitzender | - |
| McDonnell Douglas Automation | Corporate Officer/Principal | - |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Ausbildung von Charles Magness
| Lehigh University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KINETA, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Kineta One LLC
Kineta One LLC Pharmaceuticals: MajorHealth Technology Kineta One LLC provides biotechnology services. The company is headquartered in Seattle, WA. | Health Technology |
Illumigen Biosciences, Inc.
Illumigen Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Illumigen Biosciences, Inc. provides pharmaceutical research services. It develops human genetic mutations that provide roadmap for therapeutic drug mechanisms. The company's product IB657 helps to investigate the cause of apparent immunity to HCV infection. Illumigen Biosciences was founded by Dr. Charles Magness and Shawn Iadonato in 2000 and is located in Seattle, WA | Health Technology |
| McDonnell Douglas Automation | |
Kineta, Inc. (Washington)
 Kineta, Inc. (Washington) Pharmaceuticals: MajorHealth Technology Kineta, Inc. engages in the development of novel immuno-therapies. It develops a pipeline of therapies that address critical unmet patient needs in oncology, chronic pain and biodefense. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Seattle, WA. | Health Technology |
KPI Therapeutics, Inc.
KPI Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology KPI Therapeutics, Inc. operates as a clinical stage biotechnology company, which develops first in class therapies for unmet medical needs in autoimmunity. It offers dalazatide, KPI-150, and KPI-190 for systemic autoimmune diseases including lupus; and CSP conopeptide for chronic pain. The company was founded in 2013 and is headquartered in Seattle, WA. | Health Technology |
